{"id":"W4384819754","doi":"10.1200/jco.23.00402","title":"Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sumitomo Dainippon Pharma Oncology; Sierra Oncology; Bavarian Nordic; PharmaMar; Eisai; Springworks Therapeutics; Seagen; MacroGenics; Pfizer; Incyte; Moderna; Puma Biotechnology; Agios Pharmaceuticals; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Calithera Biosciences; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Array BioPharma; Exelixis; Karyopharm Therapeutics; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Temozolomide; Internal medicine; Oncology; Neutropenia; Clinical endpoint; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001527202,0.001320595,0.001302376,0.0005493592,0.000446853,0.0007208047,0.0009942842,0.001271959,0.004914191],"category_scores_gemma":[0.0008095754,0.0006392243,0.0006116909,0.0004452706,0.0006991776,0.0004509384,0.0003611816,0.001991926,0.0009592794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009202614,"about_ca_system_score_gemma":0.002161438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001522397,"about_ca_topic_score_gemma":0.003462729,"domain_scores_codex":[0.9995719,0.0002257921,0.00001654045,0.00007036622,0.00004212572,0.00007327655],"domain_scores_gemma":[0.9995908,0.00005535562,0.00006792494,0.00003970564,0.00003367821,0.0002125297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5415368,0.1383965,0.01163783,0.001218647,0.001156938,0.0007167333,0.0004250728,0.007461285,0.1508307,0.001234695,0.01942161,0.1259632],"study_design_scores_gemma":[0.5187261,0.4436472,0.01427795,0.00006875567,0.0003514185,0.0005901467,0.00008170096,0.003397694,0.008144191,0.0004737553,0.01020141,0.00003978708],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741785,0.001971762,0.001480037,0.0007500338,0.0001595255,0.01397926,0.003328281,0.0002215538,0.003931066],"genre_scores_gemma":[0.9559175,0.001736616,0.005738431,0.001940593,0.0001314215,0.01989054,0.007005382,0.00004362923,0.00759587],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004914191,"threshold_uncertainty_score":0.01643962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.250191516300431,"score_gpt":0.6109909192460797,"score_spread":0.3607994029456488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}